Corbus Pharmaceuticals Holdings has a current ratio of 4.69. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Corbus Pharmaceuticals Holdings's Current Ratio or its related term are showing as below:
CRBP'
s Current Ratio Range Over the Past 10 Years
Min: 0.74 Med: 4.05 Max: 12.31
Current: 4.69
During the past 11 years, Corbus Pharmaceuticals Holdings's highest Current Ratio was 12.31. The lowest was 0.74. And the median was 4.05.
CRBP's Current Ratio is ranked better than 57.63% of 1553
companies
in the Biotechnology industry
Industry Median: 3.77
vs CRBP: 4.69
Corbus Pharmaceuticals Holdings Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Corbus Pharmaceuticals Holdings Current Ratio Chart
Competitive Comparison of Corbus Pharmaceuticals Holdings's Current Ratio
For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corbus Pharmaceuticals Holdings's Current Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Current Ratio distribution charts can be found below:
* The bar in red indicates where Corbus Pharmaceuticals Holdings's Current Ratio falls into.
Corbus Pharmaceuticals Holdings Current Ratio Calculation
The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corbus Pharmaceuticals Holdings (NAS:CRBP) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Corbus Pharmaceuticals Holdings Current Ratio Related Terms
Thank you for viewing the detailed overview of Corbus Pharmaceuticals Holdings's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Corbus Pharmaceuticals Holdings (Corbus Pharmaceuticals Holdings) Business Description
Corbus Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics for endocannabinoid or immune systems. The company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. Corbus' internal development pipeline includes CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CRBP has been successfully added to your 